Markets:

Overview

News

Currencies

International

Treasuries

Betterlife Pharma Inc (OP:BETRF)

0.0285 -0.0038 (-11.76%)

Streaming Delayed Price Updated: 2:49 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Betterlife Pharma Inc

< Previous 1 2 Next >

BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001

September 12, 2023

From BetterLife Pharma Inc.

Via GlobeNewswire

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More ↗

July 04, 2023

World's Largest Psychedelics Conference Boasts 12K Attendees

Via Benzinga

BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives ↗

June 28, 2023

Psychedelics biotech BetterLife Pharma Inc. (OTCQB: BETRF) is fast-tracking its U.S.

Via Benzinga

BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement

September 05, 2023

From BetterLife Pharma Inc.

Via GlobeNewswire

BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives

June 27, 2023

From BetterLife Pharma Inc.

Via GlobeNewswire

BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement

July 13, 2023

From BetterLife Pharma Inc.

Via GlobeNewswire

Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah's Guest, Swiss MDMA & More ↗

June 13, 2023

Science Conference In Dubai, UAE Hosts Discussion On Psychedelics Research

Via Benzinga

BetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments Continue ↗

June 09, 2023

Psychedelics biotech BetterLife Pharma (OTCQB: BETRF) announced its non-hallucinogenic LSD derivative, BETR-001, is progressing through IND-enabling studies toward expected clinical studies targeting...

Via Benzinga

BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada

June 22, 2023

From BetterLife Pharma Inc.

Via GlobeNewswire

BetterLife Continues Progress on BETR-001 IND-Enabling Studies

June 08, 2023

From BetterLife Pharma Inc.

Via GlobeNewswire

BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California

April 25, 2023

From BetterLife Pharma Inc.

Via GlobeNewswire

BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

April 20, 2023

From BetterLife Pharma Inc.

Via GlobeNewswire

BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article

March 29, 2023

From BetterLife Pharma Inc.

Via GlobeNewswire

Promise of BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article

March 22, 2023

From BetterLife Pharma Inc.

Via GlobeNewswire

Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More ↗

March 13, 2023

Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial

Via Benzinga

Mood Disorders Could Get An Alternative Treatment With This Next-Gen, Non-Hallucinogenic Psychedelic ↗

March 09, 2023

The next-generation psychedelics R&D business is up and running, as BetterLife Pharma Inc.

Via Benzinga

BetterLife Engages Canadian Healthcare Investment Firm, Aims For Clinical Trial Programs ↗

January 26, 2023

BetterLife Pharma (OTCQB: BETRF), a non-hallucinogenic psychedelics biotech company, has contracted Bloom Burton Securities Inc. for strategic advisory services.

Via Benzinga

BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments

January 26, 2023

From BetterLife Pharma Inc.

Via GlobeNewswire

Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”

March 09, 2023

From BetterLife Pharma Inc.

Via GlobeNewswire

BetterLife Announces Closing of Private Placement

December 07, 2022

From BetterLife Pharma Inc.

Via GlobeNewswire

BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona

December 02, 2022

From BetterLife Pharma Inc.

Via GlobeNewswire

Psychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD Derivatives ↗

September 27, 2022

In parallel with working towards discovering and advancing therapeutic psychedelics, biopharma companies are continuously protecting their findings.

Via Benzinga

Study Reveals BetterLife's LSD Analogue Boosts Structural Neuroplasticity Without Hallucinogenic Side Effects ↗

August 24, 2022

A recent paper has provided new evidence that LSD has outstanding nootropic effects, believed to originate in the drug’s neuroplasticity promotion, in both animals and humans.

Via Benzinga

BetterLife's Preclinical Studies Of BETR-001 For Depression Gets Additional Sponsorship By Mitacs ↗

July 06, 2022

Biotech psychedelics company BetterLife Pharma Inc. (OTCQB: BETRF) in collaboration with the Carleton University Dept.

Via Benzinga

EXCLUSIVE: Can Non-Hallucinogenic Psychedelic Compounds Treat Mental Health Conditions? This Company Thinks So! ↗

November 15, 2021

Image Provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...

Via Benzinga

What Do You Really Know About Psychedelics And Psychedelics Stocks? ↗

June 08, 2021

According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use. That...

Via Benzinga

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗

October 18, 2021

The Week In Psychedelics

Via Benzinga

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗

October 13, 2021

Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.